Press Releases

ROCKVILLE, Md. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview
Posted: November 7, 2018
ROCKVILLE, Md. , Oct. 24, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report
Posted: October 24, 2018

Adds Phase 1 Novel Epilepsy Development Program ROCKVILLE, Md. , Sept. 13, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced

Posted: September 13, 2018

Second Appeal Win against Generic Filers ROCKVILLE, Md. , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that

Posted: September 6, 2018
Displaying 1 - 10 of 20